|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Peptide-labeled supramolecularaggregates as selective doxorubicin carriers for delivery totumor cells 显示文摘 | Morisco A Accardo A Tesauro D Palumbo R Benedetti E Morelli G | 2011 | Biopolymers *2011，96，1： | 1 |
| 2 | Noninvasive evaluation of cardiac hemodynamicsduring exercise in patients with chronic heart failure: effects of short-term coenzyme Q10treatment显示文摘 | Morisco C Nappi A Argenzizno L | 1994 | Molec Med1994，，： | 1 |
| 3 | Analysis of breath by proton transfer reaction time of flight mass spec- trometry in rats with steatohepatltis induced by high-fat diet 显示文摘 | APREA E MORISCO F BIASIOLI F A | 2012 | BiolMassSpectrom2012，47，9： | 1 |
| 4 | Influence of digitalis on left ventricular functional response to exer- cise in congestive heart failure显示文摘 | Cuocolo A Romano M | 1996 | Am J Cardiol1996，77，7： | 1 |
| 5 | Noninvasive evaluation of cardiac hemodynamics during exercise in patients with chronic heart failure: effects of short - term coenzyme Q10 treatment 显示文摘 | Morisco C Nappi A Argenziano L | 1994 | Mol Aspects Med1994，15，1： | 1 |
| 6 | Innate and Acquired Immune System in Patients Developing Interferon-α-Related Autoimmune Thyroiditis: A Prospective Study显示文摘 | G Mazziotti F Sorvillo M Piscopo F Morisco M Cioffi G Stornaiuolo G B. Gaeta A M. Molinari J H. Lazarus G Amato C Carella | 2005 | The Journal of Clinical Endocrinology & Metabolism2005，，7： | 1 |
| 7 | Etiology of and risk factors for transient and persistent aminotransferase elevation in a popula- tion of virus - free blood donors : A multicentre study 显示文摘 | Morisco F Stroffolini T Mele A et M | 2010 | Dig Liver Dis2010，42，6： | 1 |
| 8 | Influence of digitalis on left ventricular functional response to exer- cise in congestive heart failure显示文摘 | Morisco C Cuocolo A Romano M | 1996 | Am J Cardiol1996，77，7： | 1 |
| 9 | HCV infection in haemodialysed patients: A role for serum IL-10 and TGF-β1 in liver damage 显示文摘 | Burra P Masier A Morisco F | 2008 | Digestive and Liver Disease2008，40，10： | 1 |
| 10 | Polymorphism AGT2(rs4762)is involved in the development of dermatologic events:Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib显示文摘BACKGROUND Dermatologic adverse events(DAEs)are associated with a better outcome in patients with hepatocellular carcinoma(HCC)irrespective of the therapeutic agent received.The exact mechanisms associated with the development of DAEs are unknown although several studies point to direct toxicity of tyrosine kinase inhibitors(TKIs)to the skin or an immune-mediated reaction triggered by the oncologic treatment.As is the case in other conditions,individual genetic variants may partially explain a higher risk of DAEs.AIM To evaluate the contribution of several gene variants to the risk of developing DAEs in HCC patients treated with TKIs.METHODS We first analyzed 27 single-nucleotide polymorphisms(SNPs)from 12 genes selected as potential predictors of adverse event(AE)development in HCC patients treated with sorafenib[Barcelona Clinic Liver Cancer 1(BCLC1)cohort].Three additional cohorts were analyzed for AGT1(rs699)and AGT2(rs4762)polymorphisms-initially identified as predictors of DAEs:BCLC2(n=79),Northern Italy(n=221)and Naples(n=69)cohorts,respectively.The relation between SNPs and DAEs and death were assessed by univariate and multivariate Cox regression models,and presented with hazard ratios and their 95%confidence intervals(95%CI).RESULTS The BCLC1 cohort showed that patients with arterial hypertension(AHT)(HR=1.61;P value=0.007)and/or AGT SNPs had an increased risk of DAEs.Thereafter,AGT2(rs4762)AA genotype was found to be linked to a statistically significant increased probability of DAEs(HR=5.97;P value=0.0201,AA vs GG)in the Northern Italy cohort by multivariate analysis adjusted for BCLC stage,ECOG-PS,diabetes and AHT.The value of this genetic marker was externally validated in the cohort combining the BCLC1,BCLC2 and Naples cohorts[HR=3.12(95%CI:1.2-8.14),P value=0.0199,AGT2(rs4762)AA vs AG genotype and HR=2.73(95%CI:1.18-6.32)P value=0.0188,AGT2(rs4762)AA vs GG genotype].None of the other gene variants tested were found to be associated with the risk of DAE development.CONCLUSION DAE development in HCC patients receiving TKIs could be explained by the AGT2(rs4762)gene variant.If validated in other anti-oncogenic treatments,it might be considered a good prognosis marker. | Víctor Sapena Massimo Iavarone Loreto Boix Floriana Facchetti Maria Guarino Marco Sanduzzi Zamparelli Alessandro Granito Esther Samper Mario Scartozzi Josep Corominas Giorgia Marisi Alba Díaz Andrea Casadei-Gardini Laura Gramantieri Pietro Lampertico Filomena Morisco Ferran Torres Jordi Bruix María Reig | 2022 | World Journal of Hepatology2022，14，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员